Breaking Barriers: How Carthera’s SonoCloud Offers New Perspectives to Brain Cancer Patients 🧠
The American Brain Tumor Association has published an informative article for patients about our SonoCloud technology and how it's being used to treat glioblastoma.
www.abta.org/mindmatters/...
The American Brain Tumor Association has published an informative article for patients about our SonoCloud technology and how it's being used to treat glioblastoma.
www.abta.org/mindmatters/...
September 26, 2025 at 1:28 PM
Breaking Barriers: How Carthera’s SonoCloud Offers New Perspectives to Brain Cancer Patients 🧠
The American Brain Tumor Association has published an informative article for patients about our SonoCloud technology and how it's being used to treat glioblastoma.
www.abta.org/mindmatters/...
The American Brain Tumor Association has published an informative article for patients about our SonoCloud technology and how it's being used to treat glioblastoma.
www.abta.org/mindmatters/...
We have joined BlueSky!
For those new to Carthera, we are a #medtech company developing the SonoCloud, an innovative implantable ultrasound device that can temporarily disrupt the blood-brain barrier with the aim to enhance drug-delivery to the brain transforming neurological care🧠
For those new to Carthera, we are a #medtech company developing the SonoCloud, an innovative implantable ultrasound device that can temporarily disrupt the blood-brain barrier with the aim to enhance drug-delivery to the brain transforming neurological care🧠
January 13, 2025 at 10:22 AM
We have joined BlueSky!
For those new to Carthera, we are a #medtech company developing the SonoCloud, an innovative implantable ultrasound device that can temporarily disrupt the blood-brain barrier with the aim to enhance drug-delivery to the brain transforming neurological care🧠
For those new to Carthera, we are a #medtech company developing the SonoCloud, an innovative implantable ultrasound device that can temporarily disrupt the blood-brain barrier with the aim to enhance drug-delivery to the brain transforming neurological care🧠
🗓️ Meet the Carthera team in October for the latest insights into our Phase III study evaluating SonoCloud‑9 for #glioblastoma
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19
💬 Drop by our booths or send us a DM to arrange a meeting
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19
💬 Drop by our booths or send us a DM to arrange a meeting
September 9, 2025 at 3:35 PM
🗓️ Meet the Carthera team in October for the latest insights into our Phase III study evaluating SonoCloud‑9 for #glioblastoma
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19
💬 Drop by our booths or send us a DM to arrange a meeting
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19
💬 Drop by our booths or send us a DM to arrange a meeting
An intriguing way to open the blood-brain barrier on-demand. This offers hope for better treatments for glioblastoma and metastases in the brain and CNS.
www.moffitt.org/endeavor/arc...
www.moffitt.org/endeavor/arc...
Moffitt Treats First Glioblastoma Patient in Florida Using New Technology
Carthera’s Sonocloud-9 could eliminate challenges presented by the blood-brain barrier
www.moffitt.org
April 16, 2025 at 3:40 PM
An intriguing way to open the blood-brain barrier on-demand. This offers hope for better treatments for glioblastoma and metastases in the brain and CNS.
www.moffitt.org/endeavor/arc...
www.moffitt.org/endeavor/arc...
SONOBIRD is now open across 28+ sites in the EU & US!
🔗 sonobird.eu
#Glioblastoma #Ultrasound #CancerResearch #SonoCloud #Innovation #ClinicalTrial #Oncology
🔗 sonobird.eu
#Glioblastoma #Ultrasound #CancerResearch #SonoCloud #Innovation #ClinicalTrial #Oncology
sonobird.eu
January 16, 2025 at 10:08 AM
SONOBIRD is now open across 28+ sites in the EU & US!
🔗 sonobird.eu
#Glioblastoma #Ultrasound #CancerResearch #SonoCloud #Innovation #ClinicalTrial #Oncology
🔗 sonobird.eu
#Glioblastoma #Ultrasound #CancerResearch #SonoCloud #Innovation #ClinicalTrial #Oncology
Want to learn more about our Sonobird trial?
Watch this webinar with Principal Investigator, Dr Adam Sonabend where he talks about how our SonoCloud device is being used to treat #glioblastoma👇
🔗 www.youtube.com/watch?v=P66x...
#oncology #medtech
Watch this webinar with Principal Investigator, Dr Adam Sonabend where he talks about how our SonoCloud device is being used to treat #glioblastoma👇
🔗 www.youtube.com/watch?v=P66x...
#oncology #medtech
Using Ultrasound Technology To Open The Blood Brain Barrier
YouTube video by Al Musella
www.youtube.com
March 5, 2025 at 1:04 PM
Want to learn more about our Sonobird trial?
Watch this webinar with Principal Investigator, Dr Adam Sonabend where he talks about how our SonoCloud device is being used to treat #glioblastoma👇
🔗 www.youtube.com/watch?v=P66x...
#oncology #medtech
Watch this webinar with Principal Investigator, Dr Adam Sonabend where he talks about how our SonoCloud device is being used to treat #glioblastoma👇
🔗 www.youtube.com/watch?v=P66x...
#oncology #medtech
🚀 Next month, our CSO Michael Canney and Director of Preclinical Research Pierre De Rossi will attend Drug Delivery to the Brain in Colorado!🇺🇸
If you're attending, be sure to connect with Mike + Pierre to learn about SonoCloud and our SONOBIRD trial for #glioblastoma
#Neurology #Oncology #MedTech
If you're attending, be sure to connect with Mike + Pierre to learn about SonoCloud and our SONOBIRD trial for #glioblastoma
#Neurology #Oncology #MedTech
January 17, 2025 at 10:33 AM
🚀 Next month, our CSO Michael Canney and Director of Preclinical Research Pierre De Rossi will attend Drug Delivery to the Brain in Colorado!🇺🇸
If you're attending, be sure to connect with Mike + Pierre to learn about SonoCloud and our SONOBIRD trial for #glioblastoma
#Neurology #Oncology #MedTech
If you're attending, be sure to connect with Mike + Pierre to learn about SonoCloud and our SONOBIRD trial for #glioblastoma
#Neurology #Oncology #MedTech
💬 Check out this Q&A with our CCO Carole Desseaux, CSO Michael Canney, and PI Adam Sonabend on the SONOBIRD trial, exploring therapeutic ultrasound for recurrent #glioblastoma - @fusfoundation.bsky.social
👉 www.fusfoundation.org/posts/therap...
👉 www.fusfoundation.org/posts/therap...
Therapeutic Ultrasound for Recurrent Glioblastoma: A Q&A on Carthera’s Comparative Clinical Trial
Key Points Almost a year ago in February 2024, Carthera launched its large comparative SonoCloud® Blood-Brain Barrier Opening for Recurrent Disease (SONOBIRD*) clinical trial (NCT 05902169) in Europe ...
www.fusfoundation.org
January 16, 2025 at 10:08 AM
💬 Check out this Q&A with our CCO Carole Desseaux, CSO Michael Canney, and PI Adam Sonabend on the SONOBIRD trial, exploring therapeutic ultrasound for recurrent #glioblastoma - @fusfoundation.bsky.social
👉 www.fusfoundation.org/posts/therap...
👉 www.fusfoundation.org/posts/therap...
[ALA Client News] @carthera.bsky.social receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud system for glioblastoma
👉 ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
👉 ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
July 1, 2025 at 9:17 AM
[ALA Client News] @carthera.bsky.social receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud system for glioblastoma
👉 ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
👉 ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
Our innovative SonoCloud technology has been used to treat the first glioblastoma patient in Florida!
A huge thank you to @moffittnews.bsky.social for their dedication and expertise in making this possible.
Want to learn more ?
www.moffitt.org/endeavor/arc...
#Glioblastoma #ClinicalTrials
A huge thank you to @moffittnews.bsky.social for their dedication and expertise in making this possible.
Want to learn more ?
www.moffitt.org/endeavor/arc...
#Glioblastoma #ClinicalTrials
Moffitt Treats First Glioblastoma Patient in Florida Using New Technology
Carthera’s Sonocloud-9 could eliminate challenges presented by the blood-brain barrier
www.moffitt.org
April 29, 2025 at 7:46 AM
Our innovative SonoCloud technology has been used to treat the first glioblastoma patient in Florida!
A huge thank you to @moffittnews.bsky.social for their dedication and expertise in making this possible.
Want to learn more ?
www.moffitt.org/endeavor/arc...
#Glioblastoma #ClinicalTrials
A huge thank you to @moffittnews.bsky.social for their dedication and expertise in making this possible.
Want to learn more ?
www.moffitt.org/endeavor/arc...
#Glioblastoma #ClinicalTrials
It's #ClinicalTrialsDay!
Clinical trials are essential to prove the safety and efficacy of our SonoCloud system in order to improve the treatment of brain diseases such as #Glioblastoma and neurodegenerative diseases.
Clinical trials are essential to prove the safety and efficacy of our SonoCloud system in order to improve the treatment of brain diseases such as #Glioblastoma and neurodegenerative diseases.
May 20, 2025 at 7:52 AM
It's #ClinicalTrialsDay!
Clinical trials are essential to prove the safety and efficacy of our SonoCloud system in order to improve the treatment of brain diseases such as #Glioblastoma and neurodegenerative diseases.
Clinical trials are essential to prove the safety and efficacy of our SonoCloud system in order to improve the treatment of brain diseases such as #Glioblastoma and neurodegenerative diseases.
In the meantime, visit our SONOBIRD website where you can learn about our pivotal trial investigating the SonoCloud-9 in combination with carboplatin in patients undergoing planned resection for first recurrence of #glioblastoma👇
sonobird.eu
sonobird.eu
SONOBIRD: a pivotal trial in recurrent glioblastoma
SONOBIRD is a randomized, open-label, multicentric, two-arm pivotal trial comparing treatment with SonoCloud-9 combined with carboplatin versus standard of care lomustine or temozolomide in patients u...
sonobird.eu
April 9, 2025 at 2:49 PM
In the meantime, visit our SONOBIRD website where you can learn about our pivotal trial investigating the SonoCloud-9 in combination with carboplatin in patients undergoing planned resection for first recurrence of #glioblastoma👇
sonobird.eu
sonobird.eu
We are pleased to announce that SonoCloud-9 is now covered by the French government for the next 5 years!
You can learn more about the reimbursement👇
www.legifrance.gouv.fr/jorf/id/JORF...
You can learn more about the reimbursement👇
www.legifrance.gouv.fr/jorf/id/JORF...
January 14, 2025 at 10:35 AM
We are pleased to announce that SonoCloud-9 is now covered by the French government for the next 5 years!
You can learn more about the reimbursement👇
www.legifrance.gouv.fr/jorf/id/JORF...
You can learn more about the reimbursement👇
www.legifrance.gouv.fr/jorf/id/JORF...
We launched our pivotal trial, SONOBIRD last year, which will evaluate the effectiveness of the SonoCloud-9 and carboplatin to prolong life of patients with recurrent #glioblastoma in comparison with standard of care treatment.
For more details👇
sonobird.eu
#oncology #clinicaltrial #neurology
For more details👇
sonobird.eu
#oncology #clinicaltrial #neurology
Main Page (EN) - sonobird
SONOBIRD is a randomized, open-label, multicentric, two-arm pivotal trial comparing treatment with SonoCloud-9 combined with carboplatin versus standard of care lomustine or temozolomide in patients u...
sonobird.eu
January 13, 2025 at 10:22 AM
We launched our pivotal trial, SONOBIRD last year, which will evaluate the effectiveness of the SonoCloud-9 and carboplatin to prolong life of patients with recurrent #glioblastoma in comparison with standard of care treatment.
For more details👇
sonobird.eu
#oncology #clinicaltrial #neurology
For more details👇
sonobird.eu
#oncology #clinicaltrial #neurology
Exciting news! Our SonoCloud is among the first devices to receive a positive opinion from the EMA expert panel for Orphan Medical Device status, targeting recurrent glioblastoma. A big step toward CE marking!
ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
July 1, 2025 at 9:03 AM
Exciting news! Our SonoCloud is among the first devices to receive a positive opinion from the EMA expert panel for Orphan Medical Device status, targeting recurrent glioblastoma. A big step toward CE marking!
ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
ala.associates/regulatory/c...
#Glioblastoma #Oncology #MedTech #NeuroOncology
🎙️ Our CSO Michael Canney was recently featured on the Med Tech Gurus podcast, where he dives into how our SonoCloud technology works and its potential to revolutionize glioblastoma care
www.youtube.com/watch?v=3kUF...
#NeuroOncology #ClinicalTrials #Glioblastoma #MedTech
www.youtube.com/watch?v=3kUF...
#NeuroOncology #ClinicalTrials #Glioblastoma #MedTech
Breaking Barriers
YouTube video by Med Tech Gurus
www.youtube.com
September 2, 2025 at 1:06 PM
🎙️ Our CSO Michael Canney was recently featured on the Med Tech Gurus podcast, where he dives into how our SonoCloud technology works and its potential to revolutionize glioblastoma care
www.youtube.com/watch?v=3kUF...
#NeuroOncology #ClinicalTrials #Glioblastoma #MedTech
www.youtube.com/watch?v=3kUF...
#NeuroOncology #ClinicalTrials #Glioblastoma #MedTech
🔊 New podcast!
Our CSO Dr. Michael Canney joins “Michael and Mom” to talk about the BBB, glioblastoma, and how SonoCloud is changing drug delivery to the brain.
Listen here: www.youtube.com/watch?v=lvRU...
#Glioblastoma #Oncology #ClinicalTrial
Our CSO Dr. Michael Canney joins “Michael and Mom” to talk about the BBB, glioblastoma, and how SonoCloud is changing drug delivery to the brain.
Listen here: www.youtube.com/watch?v=lvRU...
#Glioblastoma #Oncology #ClinicalTrial
Michael & Mom Talk Glioblastoma Trial: Episode 63, Using Ultrasound to Break the Blood Brain Barrier
YouTube video by Michael and Mom Inspire
www.youtube.com
July 9, 2025 at 8:41 AM
🔊 New podcast!
Our CSO Dr. Michael Canney joins “Michael and Mom” to talk about the BBB, glioblastoma, and how SonoCloud is changing drug delivery to the brain.
Listen here: www.youtube.com/watch?v=lvRU...
#Glioblastoma #Oncology #ClinicalTrial
Our CSO Dr. Michael Canney joins “Michael and Mom” to talk about the BBB, glioblastoma, and how SonoCloud is changing drug delivery to the brain.
Listen here: www.youtube.com/watch?v=lvRU...
#Glioblastoma #Oncology #ClinicalTrial
🗓️ Meet the Carthera team from next week for the latest insights into our Phase III study evaluating SonoCloud 9 for #glioblastoma
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19 [Booth 9]
💬 Drop by our booths or send us a DM to arrange a meeting
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19 [Booth 9]
💬 Drop by our booths or send us a DM to arrange a meeting
September 24, 2025 at 12:33 PM
🗓️ Meet the Carthera team from next week for the latest insights into our Phase III study evaluating SonoCloud 9 for #glioblastoma
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19 [Booth 9]
💬 Drop by our booths or send us a DM to arrange a meeting
🇦🇹 #EANS2025 Vienna, 5-9 [Booth 8]
🇺🇸 #CNS2025 LA, 11-15 [Booth 588]
🇨🇿 #EANO2025 Prague, 16-19 [Booth 9]
💬 Drop by our booths or send us a DM to arrange a meeting
Lynn has been under the care of Dr Dominique Higgins and his team at UNC Chapel Hill, which is open for recruitment!
Full trial information and investigator contact details👇
sonobird.eu
#glioblastoma #oncology #clinicaltrial #medtech
Full trial information and investigator contact details👇
sonobird.eu
#glioblastoma #oncology #clinicaltrial #medtech
SONOBIRD: a pivotal trial in recurrent glioblastoma
SONOBIRD is a randomized, open-label, multicentric, two-arm pivotal trial comparing treatment with SonoCloud-9 combined with carboplatin versus standard of care lomustine or temozolomide in patients u...
sonobird.eu
February 4, 2025 at 9:16 AM
Lynn has been under the care of Dr Dominique Higgins and his team at UNC Chapel Hill, which is open for recruitment!
Full trial information and investigator contact details👇
sonobird.eu
#glioblastoma #oncology #clinicaltrial #medtech
Full trial information and investigator contact details👇
sonobird.eu
#glioblastoma #oncology #clinicaltrial #medtech
Want to know more about our Sonobird trial? Check out this Q&A with our CCO Carole Desseaux, CSO Michael Canney, and PI Adam Sonabend on therapeutic ultrasound for recurrent #glioblastoma
👉 www.fusfoundation.org/posts/therap...
👉 www.fusfoundation.org/posts/therap...
Therapeutic Ultrasound for Recurrent Glioblastoma: A Q&A on Carthera’s Comparative Clinical Trial
Key Points Almost a year ago in February 2024, Carthera launched its large comparative SonoCloud® Blood-Brain Barrier Opening for Recurrent Disease (SONOBIRD*) clinical trial (NCT 05902169) in Europe ...
www.fusfoundation.org
February 11, 2025 at 10:26 AM
Want to know more about our Sonobird trial? Check out this Q&A with our CCO Carole Desseaux, CSO Michael Canney, and PI Adam Sonabend on therapeutic ultrasound for recurrent #glioblastoma
👉 www.fusfoundation.org/posts/therap...
👉 www.fusfoundation.org/posts/therap...
🧠 On #GlioblastomaDay, we stand with the global call for better awareness, research & treatments.
Only four FDA-approved drugs & one device exist, we are working to change this through our SonoCloud system.
Read Lynn's story - a patient in our Sonobird trial👇
www.med.unc.edu/neurosurgery...
Only four FDA-approved drugs & one device exist, we are working to change this through our SonoCloud system.
Read Lynn's story - a patient in our Sonobird trial👇
www.med.unc.edu/neurosurgery...
Glioblastoma Patient Joins the Sonobird Clinical Trial at UNC Health | Department of Neurosurgery
Lynn lives an active lifestyle as an owner of her own luxury traveling tours business. But when she got back from a corporate cruise in November of 2023, she started to feel sick every day. Lynn was q...
www.med.unc.edu
July 16, 2025 at 11:11 AM
🧠 On #GlioblastomaDay, we stand with the global call for better awareness, research & treatments.
Only four FDA-approved drugs & one device exist, we are working to change this through our SonoCloud system.
Read Lynn's story - a patient in our Sonobird trial👇
www.med.unc.edu/neurosurgery...
Only four FDA-approved drugs & one device exist, we are working to change this through our SonoCloud system.
Read Lynn's story - a patient in our Sonobird trial👇
www.med.unc.edu/neurosurgery...
Our latest podcast features Michael Canney, PhD, CSO at Carthera, discussing the company’s SonoCloud-9, an implantable ultrasound device that temporarily opens the blood-brain barrier to help chemotherapy reach glioblastoma (GBM) tumors more effectively.
https://ow.ly/gJj350XjRoi
https://ow.ly/gJj350XjRoi
October 30, 2025 at 2:02 PM
Our latest podcast features Michael Canney, PhD, CSO at Carthera, discussing the company’s SonoCloud-9, an implantable ultrasound device that temporarily opens the blood-brain barrier to help chemotherapy reach glioblastoma (GBM) tumors more effectively.
https://ow.ly/gJj350XjRoi
https://ow.ly/gJj350XjRoi
In this episode, Michael Canney, PhD, CSO at Carthera, discusses the company’s SonoCloud-9, an implantable therapeutic ultrasound device designed to temporarily open the blood-brain barrier and enable drugs to reach tumors like glioblastoma more effectively. https://ow.ly/Va1w50XfFgL
Ep40: Therapeutic Ultrasound for Glioblastoma: Carthera’s Comparative Clinical Trial | Curing with Sound
In this episode of Curing with Sound, we explore a groundbreaking approach to one of medicine’s toughest cancers, glioblastoma (GBM), with Michael Canney, PhD, Chief Scientific Officer at Carthera. GBM is the most aggressive form of brain cancer, notoriously hard to treat because the blood-brain barrier (BBB) blocks many life-saving drugs from reaching tumor cells. With survival rates of just one to two years, new approaches are urgently needed.
Dr. Canney shares how Carthera’s SonoCloud-9, an implantable, therapeutic ultrasound device, temporarily opens the BBB and enhances the delivery...
ow.ly
October 21, 2025 at 4:02 PM
In this episode, Michael Canney, PhD, CSO at Carthera, discusses the company’s SonoCloud-9, an implantable therapeutic ultrasound device designed to temporarily open the blood-brain barrier and enable drugs to reach tumors like glioblastoma more effectively. https://ow.ly/Va1w50XfFgL
Feed: "Medical Device Network"
By: Ross Law on Tuesday, July 1, 2025
By: Ross Law on Tuesday, July 1, 2025
Carthera’s ultrasound system earns EMA endorsement as an orphan medical device
Carthera has received an orphan medical device status endorsement for its SonoCloud ultrasound system for treating brain disorders under a new pilot programme by the European Medicines Agency (EMA).
www.medicaldevice-network.com
July 2, 2025 at 12:36 PM
Feed: "Medical Device Network"
By: Ross Law on Tuesday, July 1, 2025
By: Ross Law on Tuesday, July 1, 2025
Arrêté du 20 décembre 2024 relatif à la prise en charge du dispositif médical implantable SONOCLOUD-9 au titre de l’article L. 165-1-1 du code de la sécurité sociale
Le dispositif médical implantable SONOCLOUD-9 est pris en charge forfaitairement par l'assurance maladie, au titre de l'article L.…
Le dispositif médical implantable SONOCLOUD-9 est pris en charge forfaitairement par l'assurance maladie, au titre de l'article L.…
Arrêté du 20 décembre 2024 relatif à la prise en charge du dispositif médical implantable SONOCLOUD-9 au titre de l’article L. 165-1-1 du code de la sécurité sociale
Le dispositif médical implantable SONOCLOUD-9 est pris en charge forfaitairement par l'assurance maladie, au titre de l'article L. 165-1-1 du code de la sécurité sociale, dans les conditions fixées par le présent arrêté, pour une durée de cinq ans et six mois à compter de la date de la première inclusion de l'étude mentionnée à l'article 2. La mise en œuvre du traitement mentionné à l'article 1er donne lieu à une étude prospective, multicentrique, contrôlée, randomisée, en deux bras parallèles, évaluant l'efficacité et la sécurité du dispositif médical implantable SONOCLOUD-9 pour la prise en charge des patients atteints d'un glioblastome en première récidive, candidats à une chirurgie.
kohenavocats.fr
December 26, 2024 at 7:12 AM
Arrêté du 20 décembre 2024 relatif à la prise en charge du dispositif médical implantable SONOCLOUD-9 au titre de l’article L. 165-1-1 du code de la sécurité sociale
Le dispositif médical implantable SONOCLOUD-9 est pris en charge forfaitairement par l'assurance maladie, au titre de l'article L.…
Le dispositif médical implantable SONOCLOUD-9 est pris en charge forfaitairement par l'assurance maladie, au titre de l'article L.…